CAR T-cell Therapies

01: Executive Summary

 

02: Scope of the Report

 

03: Introduction

3.1 CAR T-cell Therapies – Overview

3.2 CAR T-cell Therapies –Role in the treatment of various types of tumors

 

04: CAR T-cell Therapies – Pipeline Landscape

4.1 Overview of Pipeline CAR T-cell Therapies

4.2 CAR T-cell Therapies Filed and Phase III Products

4.3 Comparative Analysis

4.4 CAR T-cell Therapies Phase II Products

4.5 Comparative Analysis

4.6 CAR T-cell Therapies Phase I and IND Filed Products

4.7 Comparative Analysis

4.8 CAR T-cell Therapies Discovery and Pre-Clinical Stage Products

4.9 Comparative Analysis

4.10 CAR T-cell Therapies – Discontinued Products

4.11 CAR T-cell Therapies – Dormant Products

 

05: CAR T-cell Therapies by molecule type

5.1 Small molecule

5.2 Gene Therapies

5.3 Others

 

06: Comparative Analysis of Marketed and Pipeline CAR T-cell Therapies

 

07: Key Pipeline Product Profiles

 

08: Competitive Landscape

8.1 Prominent Vendors:

8.1a Celgene

8.2 Other Prominent Vendors:

8.2a Aeon Therapeutics

8.2b Autolus

8.2c Bellicum

8.2d Beijing Immunochina

8.2e Celyad

8.2f Eureka

8.2g Juno

8.2h Kite

8.2i Intrexon

8.2j Marino Biotechnology

8.2k Pinze Lifetechnology

8.2l Shanghai Unicar-Therapy

8.2m Sinobioway cell Therapy

8.2n Sirtex Medical

8.2o Ziopharm

 

09: Key News

9.1 Major Mergers and Acquisitions

9.2 Product News (including clinical trial progression updates)

 

 

Guide this sample report to your Inbox

Please fill in all the fields below.

Note: Your privacy is important to us. Any information you provide to us is stored on our secure servers.

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
step 1We collate your requirements.
step 2Our global research team is put into action.
step 3We deliver, and make sure your endeavour is a success!

Buy This Report